Read this company snapshot
Daily valuation snapshot
argenx SE American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $825.03
- Market capitalization (USD)
- $51,055,583,949.18
- Price / earnings (TTM)
- 39.52
- Price / book
- 6.97
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ARGX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ARGX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ARGX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $825.03 |
| Market capitalization (USD) | $51,055,583,949.18 |
| Price / earnings (TTM) | 39.52 |
| Price / book | 6.97 |
No matching rows. Clear the filter to see all records.
Read ARGX's valuation metrics
Company size
argenx SE American Depositary Shares's recorded market capitalization is $51,055,583,949.18. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
ARGX's recorded P/E is 39.52: about $39.52 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
ARGX's recorded price-to-book ratio is 6.97. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research argenx SE American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about ARGX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ARGX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.